Bristol-Myers Squibb to offload medical imaging unit
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb (BMS) is planning to divest its medical imaging unit and mulling "strategic alternatives" for its ConvaTec wound healing business in an attempt to restructure and focus on its core pharmaceutical business. The New York-based group came to its decision after it conducted a comprehensive review of its business and research and development operations.